Prochymal® phase 3 clinical trial For the treatment of Steroid-Refractory Acute GvHD
Enrollment for this Trial has been completed
The objective of this Phase 3 study is to evaluate the efficacy and safety of Prochymal in those patients who are not responding to steroid therapy. It is expected that the stem cells will distribute to areas of inflammation where they can repair the damaged tissue.
Click Here for more information
If you have questions about this clinical program, please email us at GvHD@Osiris.com